- Home
- CURI vs NERV Comparison
CURI vs NERV Comparison
Compare CURI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURI | NERV |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 207.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CURI | NERV |
|---|---|---|
| Price | $3.25 | $6.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 460.5K | 100.8K |
| Earning Date | 03-11-2026 | 02-23-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,595,000.00 | N/A |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $7.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.62 | N/A |
| 52 Week Low | $2.06 | $1.15 |
| 52 Week High | $7.15 | $12.46 |
Technical Indicators
Market Signals| Indicator | CURI | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 34.03 | 72.28 |
| Support Level | $3.03 | $4.13 |
| Resistance Level | $3.40 | $6.47 |
| Average True Range (ATR) | 0.17 | 0.53 |
| MACD | -0.03 | 0.21 |
| Stochastic Oscillator | 16.46 | 94.44 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.